Aptanomics SA, a specialist in the application of protein technologies for drug discovery, and Nanosyn Inc, a chemistry-based company applying its technology for the design, synthesis and analysis of small organic compounds for the pharmaceutical and biotechnology industries, today announced their collaboration to discover new drugs in the field of oncology.
Under the agreement, Aptanomics will use its proprietary peptide aptamer technology to screen Nanosyn's highly-reputed small organic compound libraries. Peptide aptamers are a new class of combinatorial protein reagents that guide the drug discovery effort towards druggable sites on therapeutic targets. Once initial hits are identified, Nanosyn will use its aChemistry on Demand' platform to rapidly provide Aptanomics with highly focused arrays of small molecules and further medicinal chemistry services.
Aptanomics' peptide aptamer technology provides a powerful new method to discover small molecule drugs against important pharmacological targets. u
For more information, visit www.aptanomics.com or www.nanosyn.com
